MREO News and Press, Mereo BioPharma Group From 04/30/21

Mereo BioPharma (MREO) announces a partnership with Cancer Focus Fund to evaluate its lead anti-TIGIT therapeutic antibody candidate, etigilimab, in clear cell ovarian cancer.The partnership will support a Phase 1b/2 clinical study of etigilimab in combination with an anti-PD-1...

LONDON and REDWOOD CITY, Calif. and HOUSTON, Texas, April 30, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, and Cancer Focus Fund, LP...

Mereo BioPharma Group’s stock has appreciated nicely since pricing a highly-dilutive secondary on Feb. 10, 2021. Although nearly uncovered by the Street, the company made headlines in December 2020 when it inked a collaboration with Ultragenyx that included $50 million upfront....

High-Volume Penny Stocks to Watch Right Now As another week in April comes to an end, what are the best penny stocks to watch right now? While this is not a simple question by any means, there are some solid examples of penny stocks that could be worth a closer look. This is due to a co...

LONDON and REDWOOD City, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that Company management will...

Analysts Like These Penny Stocks If you’re looking for penny stocks to buy right now, you’re not alone. The stock market as a whole is trading higher this week, thanks to economic data on Friday. Though the market was closed, that didn’t prevent the weekly jobs figu...

Nano-X Imaging (NNOX) +68% as FDA OKs 510(k) for Single Source Nanox.ARC Digital X-Ray.Chembio Diagnostics (CEMI) +48%.NanoVibronix (NAOV) +24%.Leaf Group Ltd. (LEAF) +19% on being acquired by Graham Holdings for $8.50 per share.dMY Technology Group (DMYD) +19%.Hoth Therapeutics (HO...

Mereo BioPharma Group (MREO): FY GAAP EPS of -£0.48.Cash and short-term deposits totaled £23.5 million as of December 31, 2020.Press Release For further details see: Mereo BioPharma Group reports FY results

-- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta -- -- Further Strengthened Management Team -- -- OncXerna Global Licensing Agreement for Navicixizumab -- -- Strengthened Balance Sheet through Public and Private Financings and Business Develo...

Mereo BioPharma is a biopharma company focused on oncology and rare diseases, suiting a market cap of $388M USD at the time of this article. The company currently has great partnerships in place, which will increase the chances of success as well as my confidence as an investor. M...